United Health Group, the largest U.S. health insurer by enrollees, was under pressure after Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, sent the conglomerate's chief executive, ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...

U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its blockbuster weight loss medication Zepbound in an effort to reach more ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Commissions do not affect our editors' opinions or evaluations. Medicare doesn’t cover all of your health care expenses when you turn 65. Medicare Part A covers inpatient care in hospitals and ...

Commissions do not affect our editors' opinions or evaluations. People who become eligible for Medicare coverage have two primary enrollment choices: Original Medicare and Medicare Advantage.

On Dec. 20, 2024, the FDA approved Zepbound for the treatment of moderate to severe ... That depends on what insurance you have and why the medication was prescribed. Medicare Part D will cover GLP-1 ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite missing the company’s initial sales expectations. Novo Nordisk (NVO), the ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue ... yet competition, Medicare pricing, and valuation temper long-term horizons.